medsci-skills 4.1.0

package/skills/write-paper/references/journal_profiles/Diabetes_Metabolism_Journal.md

@@ -0,0 +1,163 @@
+# Journal Profile: Diabetes & Metabolism Journal (DMJ)
+
+## Basic Information
+
+- **Publisher:** Korean Diabetes Association (KDA) — official publication
+- **Frequency:** Bimonthly — published on the first day of January, March, May, July, September, and November
+- **Impact Factor:** [TODO: verify at e-dmj.org — recent JCR year]
+- **ISSN:** [TODO: verify at e-dmj.org — print / online]
+- **Scope:** Diabetes, metabolic disorders, endocrinology — clinical and basic-science research. Particularly receptive to Korean and East Asian population studies on diabetes epidemiology, prevention, treatment, and complications.
+- **Open Access:** Yes — full open access under Creative Commons Attribution Non-Commercial License (CC BY-NC); content freely available online
+- **APC (Article Processing Charge):** [TODO: verify at e-dmj.org]
+- **Language:** English only
+- **Acceptance rate:** [TODO: verify at e-dmj.org — not stated on author instructions page]
+
+---
+
+## Manuscript Types and Word Limits
+
+| Type | Body Word Limit | Abstract | References | Figures/Tables |
+|------|----------------|----------|------------|----------------|
+| Original Article | 4,000 words (excluding abstract, references, legends) | <250 words (structured) | ≤50 | ≤6 |
+| Review Article | [TODO: verify — body limit not specified on page] | <200 words | ≤150 | [TODO: verify] |
+| Brief Report | 1,500 words (excluding references, abstract) | <180 words | ≤20 | ≤2 |
+| Editorial | [TODO: verify] | n/a | ≤20 | [TODO: verify] |
+| Letter to the Editor | 1,000 words | None | ≤10 | 1 figure OR 1 table |
+
+---
+
+## Abstract Requirements (Original Article)
+
+**Structured abstract, fewer than 250 words:**
+
+```
+Background: [Context and aim]
+Methods: [Design, population, intervention/exposure, comparator, outcomes, statistical approach]
+Results: [Primary outcome with effect sizes and 95% CIs; key secondary findings]
+Conclusion: [Main conclusion grounded in the results]
+```
+
+**Keywords:** 3–10 MeSH terms following the abstract.
+
+**Clinical trial registration:** Registration number required at the end of the abstract for clinical trials.
+
+---
+
+## Required Sections (Original Article)
+
+DMJ uses standard IMRAD structure with appropriate headings and subheadings in Methods and Results:
+
+1. **Introduction**
+2. **Methods**
+   - Subsections expected
+   - IRB approval statement required
+3. **Results**
+   - Subsections expected
+4. **Discussion**
+
+Title-page-level requirements: author affiliations, conflict-of-interest statement, disclosure of redundant publication risk, AI disclosure (see AI Policy below), corresponding-author contact.
+
+---
+
+## Statistical Reporting
+
+- "Describe the statistical analysis and the criteria for determining significance" in Methods section.
+- Professional statistician review available through the journal if needed.
+- Reporting guidelines mandated by study design (see Reporting Guidelines below).
+- [TODO: verify at e-dmj.org — specific p-value formatting, CI requirements, effect-size requirements]
+
+---
+
+## Reporting Guidelines
+
+Authors must follow appropriate reporting guidelines according to study design:
+
+- **CONSORT** — randomized controlled trials
+- **STROBE** — observational studies
+- **PRISMA** — systematic reviews and meta-analyses
+- **CARE** — case reports
+
+---
+
+## Figure and Table Requirements
+
+- **Resolution:** ≥300 DPI
+- **Format:** JPEG, EPS, TIFF, or PICT (also accepted embedded in RTF manuscripts or PDF)
+- **Photomicrographs:** Internal scale markers required
+- **Color:** Color images permitted
+- **AI-generated images:** Prohibited (see AI Policy)
+- **Maximum:** Up to 6 figures/tables for Original Article; 2 for Brief Report; 1 for Letter
+
+---
+
+## Common Rejection Reasons
+
+[TODO: confirm with editorial office or rejection-analysis source — page does not enumerate]
+
+Typical risks for any KDA-affiliated diabetes journal:
+1. **Out of scope** — manuscripts without a clear metabolic or diabetes focus may be deprioritized.
+2. **Word count overrun** — 4,000-word Original Article limit (excluding abstract, references, legends) is enforced.
+3. **Missing reporting guideline compliance** — STROBE/CONSORT/PRISMA/CARE checklist expected per study design.
+4. **Insufficient AI disclosure** — AI use must be declared on title page including tool/version/manufacturer/role.
+5. **Redundant publication risk not disclosed** — full statement required in cover letter and title page.
+
+---
+
+## Cover Letter
+
+Should include:
+
+- Full statement regarding any submissions or previous reports that might be considered redundant publications
+- Statement of any financial or other relationships that could lead to a conflict of interest
+- Manuscript title and corresponding-author contact information
+- Brief rationale for the journal as the target venue
+
+---
+
+## AI Writing Disclosure Policy
+
+- **Requirement level:** Required
+- **Permitted scope:** Authors must disclose use of AI technologies during manuscript submission, including tool names, versions, manufacturers, and the role AI played in writing
+- **Disclosure location:** Title page (statement regarding AI use must be included)
+- **AI as author:** AI cannot be listed as author or co-author
+- **AI-generated images:** Prohibited
+- **Policy URL:** https://e-dmj.org/authors/authors.php
+
+---
+
+## Author Guidelines URL
+
+https://e-dmj.org/authors/authors.php
+
+---
+
+## Submission Portal
+
+[TODO: verify at e-dmj.org — typical Korean society journals use Synapse/eM submission system]
+
+---
+
+## Positioning
+
+DMJ is well-suited for:
+- Diabetes epidemiology and incident-outcome cohort studies in Korean and East Asian populations
+- Metabolic syndrome / body composition / fatty liver studies with metabolic outcome focus
+- Single-institution observational research with diabetes-relevant primary endpoints
+- Clinical trials in diabetes management and prevention
+- Translational and mechanistic diabetes research
+
+**Cascade considerations:** Suitable as a primary submission target for Korean-cohort diabetes research and as a Tier-2 fallback after rejection from higher-IF endocrinology journals (Diabetes Care, Diabetologia, JCSM). Higher acceptance probability for region-specific population studies than Western-focused diabetes journals.
+
+| Dimension | Diabetes & Metabolism Journal | Diabetes Care | Diabetologia |
+|-----------|------------------------------|----------------|---------------|
+| Society | Korean Diabetes Association | American Diabetes Association | European Association for the Study of Diabetes |
+| Geographic emphasis | Korean / East Asian | Global, US-centric | Global, European-centric |
+| Word budget (Original) | 4,000 | [TODO: verify] | [TODO: verify] |
+| Scope flexibility | Broad — body composition, metabolic syndrome, complications, basic science | T2DM-focused, clinically driven | T2DM-focused, mechanism-oriented |
+
+
+---
+
+## Verification
+- **Source:** https://e-dmj.org/authors/authors.php
+- **Date:** 2026-05-21

package/skills/write-paper/references/journal_profiles/Diagnostic_and_Interventional_Radiology.md

@@ -0,0 +1,216 @@
+# Journal Profile: Diagnostic and Interventional Radiology
+
+## Journal Identity
+
+- **Full name**: Diagnostic and Interventional Radiology
+- **Abbreviation**: Diagn Interv Radiol (DIR)
+- **Publisher**: Galenos Publishing House, on behalf of the Turkish Society of Radiology
+- **ISSN**: 1305-3825 (print), 1305-3612 (online)
+- **Frequency**: Bimonthly (6 issues/year)
+- **Impact Factor**: ~2.7 (JCR 2023) [TODO: verify at journal site]
+- **Open Access**: Full OA (APC-based; no submission fees)
+- **Acceptance rate**: [TODO: verify at journal site]
+- **Peer review**: Double-blind; ≥2 external reviewers + statistics consultant for all originals
+
+Indexed in Science Citation Index Expanded, PubMed/MEDLINE, PubMed Central, Scopus, EMBASE, DOAJ, CINAHL, HINARI, TUBITAK ULAKBIM TR Index, Gale, CNKI.
+
+## Manuscript Types and Word Limits
+
+| Type | Body Word Limit | Abstract | References | Author Limit | Tables | Figures |
+|------|----------------|----------|------------|--------------|--------|---------|
+| Original Article | 4500 | 400 (structured) | 50 | 6* | 4 | 7 (or 15 figure parts) |
+| Review Article | 4000 | 200 | 75 | 5 | 4 | 15 (or 15 images) |
+| **Meta-Analysis** | **4000** | **200 (structured)** | **75** | **5** | **4** | **15 (or 30 figure parts)** |
+| Pictorial Essay | 1500 | 400 | 20 | 5 | 1 | 15 (or 30 figure parts) |
+| Technical Note | 1500 | 200 | 8 | 5 | 2 | 3 (or 6 figure parts) |
+| Letter to Editor | 500 | N/A | 6 | 4 | — | 2 (or 4 figure parts) |
+| Commentary | 1200 | N/A | 10 | 3 | 1 | 2 |
+| Editorial | 1200 | N/A | 10 | 3 | — | 2 (or tables) |
+
+*Original Articles with >6 authors accepted only for multicenter/multidisciplinary studies.
+
+APC (accepted only): Review $1250; Meta-Analysis $1000; Original $1000; Pictorial Essay $750; Technical Note $750.
+
+---
+
+## Abstract Requirements
+
+### Original Article (structured, ≤400 words)
+
+```
+PURPOSE: ...
+METHODS: ...
+RESULTS: ...
+CONCLUSION: ...
+CLINICAL SIGNIFICANCE: ...
+```
+
+All five subheadings are REQUIRED and must appear in capital letters. The CLINICAL SIGNIFICANCE subheading is DIR-specific and frequently missed by authors unfamiliar with the journal — editorial office desk-rejects for missing subheadings.
+
+### Meta-Analysis (structured, ≤200 words)
+
+Structured abstract required. DIR does not publish the exact subheadings for Meta-Analysis type, but PURPOSE/METHODS/RESULTS/CONCLUSION (with CLINICAL SIGNIFICANCE where applicable) is the safe default consistent with the journal's Original Article convention.
+
+### Review (≤200 words), Pictorial Essay (≤400 words), Technical Note (≤200 words): unstructured.
+
+---
+
+## Main Points (MANDATORY, 3–5 items)
+
+- Every submission (except Letters) must include a **Main Points** section with 3–5 plain-language bullets summarizing the most striking findings.
+- **Location**: Between Abstract and Introduction (per Author Guidelines and editorial office guidance).
+  - NOTE: The Submission Checklist PDF states "at the end of the main document", which conflicts with the Guidelines. When the editorial office flags position, place between Abstract and Introduction.
+- Target audience: radiology residents, specialists from other fields, and radiology experts — keep language simple.
+- Minimum 3 items required; fewer items triggers desk return.
+
+---
+
+## Required Sections (Original Article and Meta-Analysis)
+
+1. **Introduction** — brief nature and purpose, relevant literature.
+2. **Methods** — must include:
+   - Clinical and technical procedures.
+   - **Research ethics standards compliance**: IRB/ethics committee approval statement with decision/protocol number; Declaration of Helsinki statement if no IRB exists at the institution.
+   - **Informed consent** statement (obtained, waived for retrospective, or N/A with reason). For systematic reviews/meta-analyses of published data, explicitly state that IRB approval and informed consent were not required.
+   - **Statistical Analysis** subsection — tests named; uncommon methods cited.
+3. **Results** — clear and without comment; include statistical analysis results.
+4. **Discussion** — contextualize findings; explicitly state limitations/drawbacks in the paragraph before the conclusion; strong closing paragraph.
+5. **Conclusion** — one paragraph (integrated into Discussion closing or as separate subheading).
+6. **Main Points** (3–5 bullets) — position between Abstract and Introduction.
+
+---
+
+## Statistical Reporting
+
+DIR enforces a specific biostatistical reporting policy; all originals are evaluated by a statistics consultant.
+
+- **p-values**: 3 decimal places (e.g., p = 0.025; p = 0.524). If software output shows p = 0.000, report as **p < 0.001**.
+- **Distribution-appropriate summaries**:
+  - Normally distributed → mean ± SD.
+  - Non-normal → median with min–max, range (R), or interquartile range (IQR).
+- **Statistical tests**: Name each test explicitly in the Methods **Statistical Analysis** subsection. Uncommon or non-standard methods must be supported with references.
+- **Software**: Identify software, version, and manufacturer (e.g., "SPSS Statistics 28, IBM Corp.").
+- **95% CI** for primary outcomes (ICMJE/Altman 1983 default applies).
+- **Reporting guideline compliance**: CONSORT (RCT), STROBE (observational), STARD (diagnostic accuracy), **PRISMA / PRISMA-DTA (systematic reviews and meta-analyses)**, TREND (non-randomized behavioral/public health).
+
+---
+
+## Figures
+
+- **Format**: JPG or TIFF, submitted as standalone files through the submission system (not embedded).
+- **Resolution**: minimum 300 DPI.
+- **Flowchart**: First figure (Figure 1) of Original Articles must be the study flowchart (PRISMA flowchart for meta-analyses).
+- **Subunits**: Label panels a, b, c in the bottom-left corner in Times New Roman 10pt (white on dark background, black on light).
+- **Blinding**: All identifying information (institution, patient IDs) must be removed from images.
+- **Reuse**: Written permission from copyright holder required for previously published material; cite original in references and below reprinted material.
+
+## Tables
+
+- Inserted in the main document using Word's "insert table" command (not as separate file).
+- Listed at the end of the main document after references.
+- Descriptive title above; abbreviations defined in footnotes below each table.
+- Numbered sequentially by order of first citation.
+
+## Manuscript Format
+
+- **Font**: Times New Roman, 12 pt, 1.5 line spacing.
+- **Blinding**: Main document must not contain any author, institution, grant, or acknowledgement information — all such content goes on the separate Title Page.
+- **Abbreviations**: Defined at first use in BOTH abstract and main text, with abbreviation in parentheses.
+- **Product citations**: In-text as "Product (Manufacturer)" — e.g., "Discovery ST PET/CT scanner (GE Healthcare)".
+- **Sequential numbering**: References, tables, and figures all numbered in order of first text citation.
+
+---
+
+## References
+
+- **Style**: AMA Manual of Style.
+- **In-text format**: **Parenthetical**, not superscript or bracketed (e.g., "(5)" or "(5, 7–9)").
+- **Order**: Sequential by first appearance in text.
+- **Journal abbreviations**: Per Index Medicus / MEDLINE / PubMed.
+- **Author listing**: ≤6 authors → list all; ≥7 → first 3 followed by "et al."
+- **Preprints**: Citable with title, server name, DOI, when substantive to the topic. Not citable if the preprint has since been formally published.
+
+Example journal article:
+> Economopoulos KJ, Brockmeier SF. Rotator cuff tears in overhead athletes. Clin Sports Med. 2012;31(4):675-692.
+
+---
+
+## Common Rejection Reasons
+
+1. **Desk return for guideline non-compliance** (editorial office pre-check):
+   - Missing CLINICAL SIGNIFICANCE (or any of 5 required) abstract subheadings.
+   - Missing Main Points section or <3 items.
+   - Missing Statistical Analysis heading.
+   - Missing informed consent / IRB statement in Methods (even for SR/MA where both are N/A).
+   - Non-sequential figure/table/reference citations.
+   - Superscript or bracketed reference citations (must be parenthetical).
+   - Supplementary material submitted as PDF (must be Word).
+2. **iThenticate failure**: Overall similarity >20% or single-source duplication ≥5% → auto-return with report.
+3. **Blinding violation**: Author names, institutions, or grant numbers in main document.
+4. **Insufficient priority** (at Editor-in-Chief / Section Editor level) — scope or novelty.
+5. **Statistical methodology issues** flagged by the statistics consultant.
+
+---
+
+## Cover Letter
+
+Must include:
+- Brief statement of existing knowledge and the contribution the study makes.
+- Statement from corresponding author accepting responsibility for authorship during submission and review.
+- Disclosure of any preprint deposition, including preprint DOI.
+- Disclosure of any prior meeting abstracts with overlapping material.
+
+---
+
+## AI Writing Disclosure Policy
+
+- **Requirement level:** Not specified — follows ICMJE recommendations.
+- **Permitted scope:** Language editing only — per ICMJE 2025 (DIR explicitly endorses ICMJE Recommendations May 2022 for manuscript preparation).
+- **Disclosure location:** Methods.
+- **AI-generated images:** Not specified.
+- **Policy URL:** https://www.dirjournal.org/ (Instructions to Authors; no dedicated AI policy page as of 2026-04).
+
+[VERIFY] DIR Instructions to Authors do not contain a dedicated AI/LLM clause. ICMJE defaults applied; verify at journal site before final submission.
+
+---
+
+## Submission Logistics
+
+- **Platform**: Manuscript Manager (Galenos) — https://www.dirjournal.org/
+- **Documents required**:
+  1. Main document (blinded, Word, TNR 12pt 1.5 spacing, including Abstract → Main Points → Introduction → … → References → Tables → Figure Legends).
+  2. Title Page (separate Word): title, authors with affiliations and ORCID, corresponding author contact (address, mobile, email), grants/acknowledgements.
+  3. Figures (standalone JPG or TIFF, ≥300 DPI).
+  4. Supplementary materials as **Word** (not PDF).
+  5. Cover Letter.
+  6. **Copyright Agreement Form** (wet-signed, scanned PDF): https://cms.galenos.com.tr/SolvePark/Uploads/Files/DIR-Copyright%20.pdf
+     - May be signed per-author for large or international groups.
+- **Revisions**: 30-day window from decision letter; request extension before expiry. Include point-by-point Author's Response with line numbers for each change, plus annotated and clean copies of main document.
+
+---
+
+## Author Guidelines URL
+
+https://www.dirjournal.org/ (Instructions to Authors section)
+
+Checklists:
+- Submission checklist: https://cms.galenos.com.tr/SolvePark/Uploads/Files/DIR-Submission-Checklist.pdf
+- Biostatistical reporting: https://cms.galenos.com.tr/SolvePark/Uploads/Files/Biostatistical-Reporting-Considerations-and-Suggestions.pdf
+- Copyright form: https://cms.galenos.com.tr/SolvePark/Uploads/Files/DIR-Copyright%20.pdf
+
+---
+
+## Positioning
+
+**When to submit here**: Diagnostic radiology, interventional radiology, and imaging-based diagnostic accuracy studies, especially meta-analyses and technical innovations suited to a bimonthly society journal with fast OA turnaround. Favorable for Turkish and regional radiology groups, and for methodologically sound but narrower-scope work that may not fit Radiology or European Radiology.
+
+**When NOT to submit here**: Studies targeting a broader audience or aiming for highest-tier impact (send to Radiology, Radiology: AI, European Radiology, JACR). Subspecialty-focused work in IR should weigh CVIR or JVIR first. Non-radiology imaging (pure pathology, ultrasound in non-radiology settings) may fit poorly with scope.
+
+| Dimension | DIR | European Radiology | Clinical Radiology | CVIR |
+|-----------|-----|-------------------|--------------------|---|
+| Society | Turkish Soc. of Radiology | ESR | RCR (UK) | CIRSE |
+| Scope | Diagnostic + IR, general | Diagnostic radiology (broad) | Diagnostic radiology (UK focus) | Interventional radiology only |
+| Impact factor (JCR 2023) | ~2.7 | ~5.9 | ~2.1 | ~2.8 |
+| Emphasis | MA, original, technical notes; statistical rigor via stat consultant | Prospective multicenter, AI, novel imaging | Broad including audit/QI | IR technique, devices, outcomes |
+| OA | Full OA (APC) | Hybrid | Hybrid | Hybrid |
+| Double-blind | Yes | No (single-blind) | No | No |

package/skills/write-paper/references/journal_profiles/Endocrinology_and_Metabolism.md

@@ -0,0 +1,167 @@
+# Journal Profile: Endocrinology and Metabolism (EnM)
+
+## Basic Information
+
+- **Publisher:** Korean Endocrine Society (KES) — official publication
+- **Frequency:** [TODO: verify at e-enm.org — not stated on author instructions page]
+- **Impact Factor:** [TODO: verify at e-enm.org — recent JCR year]
+- **ISSN:** [TODO: verify at e-enm.org — print / online]
+- **Scope:** Endocrinology, metabolism, hormonal disorders, thyroid, adrenal, pituitary, bone metabolism, diabetes, lipid metabolism — clinical and basic-science research. Particularly receptive to Korean and East Asian population studies on endocrine disorders.
+- **Open Access:** Yes — full open access; content is freely available online, downloadable, and printable
+- **APC (Article Processing Charge):** [TODO: verify at e-enm.org]
+- **Language:** English only
+- **Acceptance rate:** [TODO: verify at e-enm.org — not stated on author instructions page]
+
+---
+
+## Manuscript Types and Word Limits
+
+| Type | Body Word Limit | Abstract | References | Figures/Tables |
+|------|----------------|----------|------------|----------------|
+| Original Article | [TODO: verify — body limit not stated on page] | ≤250 words (structured) | ≤50 | [TODO: verify] |
+| Review Article | [TODO: verify] | ≤200 words | ≤150 | [TODO: verify] |
+| Brief Report | 1,200 words | ≤150 words (unstructured) | ≤20 | ≤2 |
+| Editorial | 1,000 words | n/a | ≤20 | [TODO: verify] |
+| Image | 1,000 words | n/a | ≤5 | [TODO: verify] |
+| Letter to the Editor | 1,000 words | n/a | ≤10 | ≤1 |
+
+---
+
+## Abstract Requirements (Original Article)
+
+**Structured abstract, ≤250 words:**
+
+```
+Background: [Context and aim]
+Methods: [Design, population, intervention/exposure, comparator, outcomes, statistical approach]
+Results: [Primary outcome with effect sizes and 95% CIs; key secondary findings]
+Conclusion: [Main conclusion grounded in the results]
+```
+
+**Keywords:** [TODO: verify keyword count and MeSH requirement at e-enm.org]
+
+---
+
+## Required Sections (Original Article)
+
+EnM uses standard IMRAD structure with headings and subheadings in Methods and Results:
+
+1. **Introduction**
+2. **Methods**
+   - Subsections expected
+3. **Results**
+   - Subsections expected
+4. **Discussion**
+
+Title-page-level requirements: full author list, conflict-of-interest statement, AI disclosure (see AI Policy below), corresponding-author contact, redundant-publication disclosure.
+
+---
+
+## Statistical Reporting
+
+[TODO: verify at e-enm.org — specific p-value formatting, CI requirements, effect-size requirements not enumerated on author instructions page]
+
+---
+
+## Reporting Guidelines
+
+EnM requests authors follow reporting guidelines according to study design:
+
+- **CONSORT** — randomized controlled trials
+- **STROBE** — observational studies
+- **PRISMA** — systematic reviews and meta-analyses
+- **STARD** — diagnostic accuracy studies
+
+---
+
+## Peer Review
+
+- **Type:** Double-blind — both authors and reviewers remain anonymous
+- **Reviewer count:** Three anonymous reviewers who are specialists in the relevant field
+- **Review period:** Maximum 3 months
+
+---
+
+## Figure and Table Requirements
+
+- **Resolution:** Exceeds 300 DPI
+- **Format:** JPEG, GIF, TIFF, BMP, or PICT
+- **Numbering:** Sequential Arabic numerals; letters for sub-panels (Fig. 1A, 1B)
+- **Color:** [TODO: verify color policy and online/print distinction at e-enm.org]
+- **Maximum:** [TODO: verify for Original Article; explicit limits given only for Brief Report (≤2), Letter (≤1)]
+
+---
+
+## Common Rejection Reasons
+
+[TODO: confirm with editorial office — page does not enumerate]
+
+Typical risks for any KES-affiliated endocrinology journal:
+1. **Out of scope** — submissions without a clear endocrine, metabolic, or hormonal focus may be deprioritized.
+2. **Insufficient endocrinology framing** — body composition, diabetes, or metabolic studies without explicit hormonal-axis or endocrine-mechanism discussion may be redirected to sibling journals.
+3. **Missing reporting guideline compliance** — STROBE/CONSORT/PRISMA/STARD checklist expected per study design.
+4. **AI disclosure non-compliance** — failure to disclose AI use in cover letter and manuscript may result in rejection or retraction.
+5. **Redundant publication risk not disclosed** — full statement required in cover letter regarding any prior submissions or related reports.
+
+---
+
+## Cover Letter
+
+Must include:
+
+- Full statement to the editor about all submissions and previous reports that might be regarded as redundant publication
+- Conflict-of-interest statement
+- Attestation that all authors approved the manuscript and meet authorship criteria
+- Corresponding-author contact information
+- AI use disclosure (if applicable; also in manuscript)
+
+---
+
+## AI Writing Disclosure Policy
+
+- **Requirement level:** Required when AI-assisted technologies are used
+- **Permitted scope:** "Authors should clearly describe how they used AI in the submitted manuscript and in their cover letter. Authors are fully responsible for the scientific integrity of AI-generated content."
+- **Disclosure location:** Both cover letter AND manuscript
+- **AI as author:** AI cannot be listed as author or co-author
+- **AI-generated images:** [TODO: verify at e-enm.org — not explicitly addressed on author instructions page]
+- **Non-disclosure penalty:** Results in rejection or retraction
+- **Policy URL:** https://e-enm.org/authors/authors.php
+
+---
+
+## Author Guidelines URL
+
+https://e-enm.org/authors/authors.php
+
+---
+
+## Submission Portal
+
+[TODO: verify at e-enm.org]
+
+---
+
+## Positioning
+
+EnM is well-suited for:
+- Endocrinology and hormonal-axis studies in Korean and East Asian populations
+- Thyroid, adrenal, pituitary, bone metabolism, lipid, and diabetes research with explicit endocrine framing
+- Single-institution observational endocrinology research
+- Translational and mechanistic endocrine studies
+- Population-based metabolic outcome studies with hormonal-axis discussion
+
+**Cascade considerations:** Suitable as a primary submission target for Korean-cohort endocrinology research with explicit hormonal-axis or endocrine-mechanism framing, and as a Tier-3 fallback after rejection from higher-IF diabetes/endocrinology journals (Diabetes Care, Diabetologia, JCSM, Diabetes & Metabolism Journal). Higher acceptance probability for region-specific endocrinology studies than Western-focused journals.
+
+| Dimension | Endocrinology and Metabolism | Diabetes & Metabolism Journal | Lancet Diabetes & Endocrinology |
+|-----------|------------------------------|-------------------------------|--------------------------------|
+| Society | Korean Endocrine Society | Korean Diabetes Association | Lancet family |
+| Geographic emphasis | Korean / East Asian | Korean / East Asian | Global, high-impact |
+| Scope | Broad endocrinology (thyroid, adrenal, pituitary, bone, diabetes, lipid) | Diabetes-focused metabolic | Diabetes-focused with global RCT/cohort emphasis |
+| Peer review timeline | ≤3 months | [TODO: verify] | [TODO: verify] |
+
+
+---
+
+## Verification
+- **Source:** https://e-enm.org/authors/authors.php
+- **Date:** 2026-05-21